AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$5.82 USD
+0.01 (0.17%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $5.82 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANGO 5.82 +0.01(0.17%)
Will ANGO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANGO
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
ANGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
AngioDynamics (ANGO) Settles Patent Litigations With BD
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
Other News for ANGO
Insiders Buying Zumiez And 3 Other Stocks
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities
Biggest stock mover today: GCTS, TSVT, GRIN, ANGO, ATUS, and more
Check-Cap, Outset Medical, Vincerx Pharma among healthcare movers